findmyKOL

Michael Via

Basic profile

Mount Sinai Beth Israel

ORCIDNone on fileNPI
RegionNew York, NY · NortheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Michael Via is an Endocrinology/Metabolic physician affiliated with Mount Sinai Beth Israel. OpenAlex indexes 64 publications with 1,014 citations (h-index 13).

Overview

Scholarship

indexed output and impact (OpenAlex)
64publications

Distinct works indexed by OpenAlex.

1,014citations

Total citations across indexed works.

13h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
5companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

5 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    57.3%
    Insulin Analog15.9%
    Novolog Flexpen23%Basaglar Kwikpen U-10019%Tresiba Flextouch U-20016%Humalog Kwikpen U-10013%Lantus Solostar9%Levemir Flextouch6%Levemir Flexpen5%Insulin Lispro Kwikpen U-1004%Novolog3%Tresiba Flextouch U-1003%
    Part D<11 patients
    Biguanide (metformin)10.3%
    Metformin Hcl72%Metformin Hcl Er28%
    Part D61 patients

    + 8 more classes in this area

  • Hormonal (systemic)

    22.3%
    l-Thyroxine17.7%
    Levothyroxine Sodium76%Synthroid24%
    Part D98 patients
    Calcium-sensing Receptor Agonist1.7%
    Cinacalcet Hcl100%
    Part D<11 patients

    + 3 more classes in this area

  • Cardiovascular

    17.9%
    Statin7.5%
    Atorvastatin Calcium65%Rosuvastatin Calcium35%
    Part D35 patients
    Angiotensin receptor blocker (ARB)3.6%
    Losartan Potassium88%Valsartan12%
    Part D<11 patients

    + 7 more classes in this area

Where care is delivered (Part B)16% facility · 84% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”